Addison's disease Medical Services in China

Addison's disease, also known as primary adrenal insufficiency, is a rare, chronic endocrine disorder characterized by inadequate production of cortisol and often aldosterone by the adrenal cortex. This deficiency arises from autoimmune destruction of the adrenal glands in approximately 80–90% of cases in developed countries—where the body’s immune system mistakenly targets and damages adrenal cortical tissue. Other causes include infections (e.g., tuberculosis, HIV-associated mycobacterial or fungal infections), bilateral adrenal hemorrhage, metastatic cancer, genetic disorders (e.g., autoimmune polyglandular syndrome type 1, adrenoleukodystrophy), and surgical removal of the adrenals. The pathogenesis centers on glucocorticoid and mineralocorticoid deficiency: cortisol regulates metabolism, immune response, stress adaptation, and blood pressure; aldosterone maintains sodium-potassium balance and intravascular volume. Without replacement, patients face life-threatening adrenal crises—marked by profound hypotension, hyponatremia, hyperkalemia, hypoglycemia, vomiting, confusion, and shock. Epidemiologically, Addison’s disease affects about 100–140 per million people globally, with an annual incidence of 4–6 new cases per million. It occurs equally across sexes and most commonly presents between ages 30–50, though it can manifest at any age—including childhood in genetic forms. Risk factors include personal or family history of autoimmune diseases (e.g., type 1 diabetes, Hashimoto’s thyroiditis, vitiligo), prior tuberculosis exposure (especially in endemic regions), HIV infection, antiphospholipid syndrome, and use of anticoagulants predisposing to adrenal hemorrhage. Quality of life is significantly impacted: fatigue, orthostatic dizziness, weight loss, gastrointestinal distress, depression, and reduced exercise tolerance are common—even with treatment. Patients require lifelong hormone replacement and vigilant self-management, including stress-dose steroid adjustment during illness or injury. Psychological burden is substantial due to unpredictability of crises, medication adherence demands, and social stigma around chronic invisible illness. Pregnancy requires specialized endocrinology oversight to prevent maternal-fetal complications. Early diagnosis remains challenging due to nonspecific, insidious symptoms—leading to delays averaging 3–6 months from symptom onset to confirmation via morning serum cortisol, ACTH, and ACTH stimulation test. With timely, individualized glucocorticoid (hydrocortisone or prednisone) and mineralocorticoid (fludrocortisone) replacement, life expectancy approaches normal, but mortality remains elevated compared to the general population—primarily due to delayed crisis recognition and suboptimal dosing.

Treatment Options & Itemized Cost Breakdown: Addison’s Disease (Endocrinology)

Non-Surgical / Conservative Management

*Primary treatment is lifelong glucocorticoid and mineralocorticoid replacement.*

• •Glucocorticoid Replacement (e.g., hydrocortisone)

- *Target criteria:* Confirmed ACTH stimulation test failure, low morning cortisol (<3 µg/dL), elevated ACTH (>100 pg/mL)

- *Tiered dosing & cost (per month, USD):* - Standard dose (15–25 mg/day oral): $12–$18 - Stress-dose regimen (IV hydrocortisone 100 mg bolus + 200 mg): $45–$65 (per acute episode)

• •Mineralocorticoid Replacement (fludrocortisone acetate)

- *Target criteria:* Hyperkalemia (>5.0 mmol/L), hyponatremia (<135 mmol/L), orthostatic hypotension

- *Monthly cost (0.05–0.2 mg/day):* $8–$14

• •Essential Monitoring & Lab Fees (per visit, USD):

- Serum electrolytes (Na⁺, K⁺), renin, aldosterone: $22

- Morning cortisol & ACTH: $38 - Renal function panel (BUN, creatinine, eGFR): $16 - Annual bone density (DEXA): $75

Surgical/Procedural Options

*Surgery is NOT indicated for primary adrenal insufficiency itself. Intervention is reserved solely for treatable underlying causes.*

• •Adrenalectomy (bilateral)

- *Eligibility:* Confirmed bilateral adrenal metastases (e.g., from lung cancer) causing ectopic ACTH syndrome *mimicking* Addison’s — rare and requires oncologic confirmation

- *Procedure cost (Grade 3A hospital, USD):* $4,200–$5,800 - *Preoperative workup (mandatory):* CT abdomen/pelvis ($110), PET-CT ($320), tumor markers ($48)

• •Pituitary Surgery (transsphenoidal)

- *Eligibility:* Secondary adrenal insufficiency due to *resectable* non-functioning pituitary macroadenoma compressing corticotrophs

- *Procedure cost:* $3,900–$5,100 - *Preoperative MRI pituitary with contrast:* $145

Special/Complex Condition Management

• •Adrenal Crisis (Emergency ICU Admission)

- IV hydrocortisone, fluid resuscitation, vasopressor support, infection workup

- *24-hour ICU stabilization (USD):* $1,350–$1,900

• •Autoimmune Polyglandular Syndrome (APS-1/APS-2)

- Requires concurrent management of thyroiditis, type 1 diabetes, or hypoparathyroidism

- *Annual multidisciplinary coordination fee (endocrinology + immunology):* $210

Quick Selection Guide

• •Young adult (<40), newly diagnosed, no comorbidities: Start standard hydrocortisone + fludrocortisone; budget $25–$35/month
• •Elderly (>70) with heart failure or CKD: Lower hydrocortisone dose (10–15 mg/day), avoid fludrocortisone if eGFR <30 mL/min; prioritize electrolyte monitoring ($22/visit)
• •Low-income patient: Generic hydrocortisone ($12/month) + public hospital lab subsidies (electrolytes $12, cortisol $24)
• •Acute crisis presentation: Immediate IV hydrocortisone + ICU admission — total first 48h cost $1,800–$2,300
• •Suspected secondary cause (e.g., pituitary mass): Prioritize MRI ($145) before endocrine referral; surgery only if mass confirmed and compressive